We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
- Authors
Jüni, Peter; Nartey, Linda; Reichenbach, Stephan; Sterchi, Rebekka; Dieppe, Paul A; Egger, Matthias
- Abstract
The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An increased risk of myocardial infarction had been observed in 2000 in the Vioxx Gastrointestinal Outcomes Research study (VIGOR), but was attributed to cardioprotection of naproxen rather than a cardiotoxic effect of rofecoxib. We used standard and cumulative random-effects meta-analyses of randomised controlled trials and observational studies to establish whether robust evidence on the adverse effects of rofecoxib was available before September, 2004.
- Publication
Lancet (London, England), 2004, Vol 364, Issue 9450, p2021
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(04)17514-4